Amicus Therapeutics, Inc. Stock News

Amicus (FOLD) Q2 Revenue Jumps 22%

Amicus Therapeutics is building momentum with strong sales growth from GALAFOLD and POMBILITI/OPFOLDA, targeting $1 billion in revenue by 2028. The DMX-200 licensing deal opens a major market opportunity in FSGS, with positive interim phase 3 data and potential for broader rare renal indications. Financially, Amicus has limited cash but can raise more through its ATM facility, and its approved ...

Amicus Therapeutics, Inc. (NASDAQ:FOLD ) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Company Participants Andrew Faughnan - Vice President of Investor Relations Bradley L. Campbell - CEO, President & Director Jeffrey P.

Q2 2025 Total Revenue of $154.7M, up 18% at CER Galafold ® Q2 Revenue of $128.9M, up 12% at CER Pombiliti ® + Opfolda ® Q2 Revenue of $25.8M, up 58% at CER Reiterating 2025 Financial Guidance including GAAP Profitability During H2 2025 Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N.J.

American Securities Association and Citadel Securities LLC v. U.S. Securities and Exchange Commission American Securities Association and Citadel Securities LLC v. U.S. Securities and Exchange Commission

PRINCETON, N.J., July 21, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, July 31, 2025, at 8:30 a.m.

PHILADELPHIA , July 10, 2025 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Amicus Therapeutics, Inc. (NASDAQ: FOLD) ("Amicus") on behalf of the company's shareholders.  Year to date, shares of Amicus' stock have declined over 32% in value, to trade at a current price of less than $7.00 per share.

PRINCETON, N.J., and TOKYO, June 25, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat) for the treatment of adult patients with late-onset Pompe disease (LOPD).